No Data
No Data
Express News | Anavex Life Sciences Corp - Top Line Data Expected in Second Half of 2025
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia
Express News | Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of Anavex®3-71 for the Treatment of Schizophrenia
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
12 Health Care Stocks Moving In Monday's After-Market Session
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn